Neurocognitive, Social-Cognitive and Quality of Life Differences in Children with Advanced Heart Failure: A Single-Center Cross-Sectional Study
Abstract
Highlights What are the main findings? • Decreased global cognition (WISC-IV), social cognition (Eyes Test), health-related quality of life (both child and parent), higher parent-reported anxiety, and similar child-reported anxiety.• No cognitive differences among the LVAD/transplant/waiting groups. What are the implications of the main findings? • Parent and child self-reports provide complementary information.• Neurocognitive vulnerability exists in all heart failure patient groups. Healthcare should be planned considering the neurocognitive and social development. Abstract Background: Children with heart failure (HF) are at risk of cognitive and psychiatric problems, and reduced health-related quality of life (QoL), yet data remain limited. This study compared neurocognition, social cognition, health-related quality of life, and psychiatric symptoms among children awaiting transplantation with or without ventricular assist devices (VADs), those who had undergone heart transplantation, and matched controls. Methods: Twenty-three patients at Ege University and 17 age- and sex-matched controls were assessed using the Schedule for Affective Disorders and Schizophrenia for School-Aged Children, Present and Lifetime Version (K-SADS-PL), Screen for Child Anxiety-Related Emotional Disorders (SCARED), Children’s Depression Inventory (CDI), Wechsler Intelligence Scale for Children–Fourth Edition (WISC-IV), Eyes Test, and Pediatric Quality of Life Inventory (PedsQL), evaluating…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 7 participants or records.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.